| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | simvastatin | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.086 | 0.8 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |